Reducing the levels of the protein NEK2 in the pulmonary arteries may reverse vascular remodeling in PAH, a rat study showed.

Immunosuppression appears to reduce mortality among people with systemic sclerosis with pulmonary arterial hypertension but ...

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure and ...

Right ventricular hypertrophy, right ventricular systolic pressure, and vascular remodeling—all complications of pulmonary hypertension—were reduced as compared with controls that did not ...

Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merck’s sotatercept. Backed by $97.5M, results will ...

cholesterol the role of natriuretic peptide signaling and mineralocorticoid receptor antagonism in protecting against adverse remodeling in the pressure-overloaded heart the molecular pathogenesis of ...

cholesterol the role of natriuretic peptide signaling and mineralocorticoid receptor antagonism in protecting against adverse remodeling in the pressure-overloaded heart the molecular pathogenesis of ...

"We know that during the remodeling process fibroblasts are activated," said Cheng Hong, MD, Ph.D., pulmonary vascular medicine specialist at the First Affiliated Hospital of Guangzhou Medical ...

Over time, the small pulmonary arteries thicken and become blocked due to a progressive accumulation of cells in the vascular wall. Sotatercept works as an “activin receptor ligand trap” and ...